ReviewNeuroscience bulletin2026
Oligodendroglia as Active Immunomodulators in Demyelinating Diseases.
Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Oligodendrocytes (OLs) and oligodendrocyte progenitor cells (OPCs) are essential central nervous system (CNS) cell types responsible for myelin formation, efficient signal conduction, and axonal homeostasis. While the immunological functions of other glial cells-microglia and astrocytes-are well established, the involvement of oligodendrocyte lineage cells (OLCs) in the CNS inflammation has only recently gained recognition. Under pathological conditions, particularly during demyelination, OLCs transition into disease-associated states characterized by the release of pro- and anti-inflammatory chemokines and cytokines once thought to be exclusive to immune cells, thereby challenging their traditional characterization as passive victims. Elucidating the precise immunomodulatory roles of OLCs within the neural microenvironment may be pivotal for promoting regeneration following neuroinflammation in demyelinating CNS diseases. This review focuses on the immunological profiles of OLCs, the mechanisms driving their immunomodulatory phenotypes, their interactions within the neural microenvironment, and the implications of these processes in both physiological and pathological contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.